Lipid Status of A2780 Ovarian Cancer Cells after Treatment with Ruthenium Complex Modified with Carbon Dot Nanocarriers: A Multimodal SR-FTIR Spectroscopy and MALDI TOF Mass Spectrometry Study
Autori
Nešić, Maja D.Dučić, Tanja
Algarra, Manuel
Popović, Iva A.
Stepić, Milutin
Gonçalves, Mara
Petković, Marijana
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
In the last decade, targeting membrane lipids in cancer cells has been a promising approach that deserves attention in the field of anticancer drug development. To get a comprehensive understanding of the effect of the drug [Ru(η5-Cp)(PPh3)2CN] (RuCN) on cell lipidic components, we combine complementary analytical approaches, matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI TOF MS) and synchrotron radiation-based Fourier transform infrared (SR-FTIR) spectroscopy. Techniques are used for screening the effect of potential metallodrug, RuCN, without and with drug carriers (carbon dots (CDs) and nitrogen-doped carbon dots (N-CDs)) on the lipids of the human ovarian cancer cell line A2780. MALDI TOF MS results revealed that the lysis of ovarian cancer membrane lipids is promoted by RuCN and not by drug carriers (CDs and N-CDs). Furthermore, SR-FTIR results strongly suggested that the phospholipids of cancer cells undergo oxidative stress after the trea...tment with RuCN that was accompanied by the disordering of the fatty acid chains. On the other hand, using (N-)CDs as RuCN nanocarriers prevented the oxidative stress caused by RuCN but did not prevent the disordering of the fatty acid chain packing. Finally, we demonstrated that RuCN and RuCN/(N-)CDs alter the hydration of the membrane surface in the membrane–water interface region.
Ključne reči:
anticancer Ru metallodrug / carbon dots / drug nanocarriers / lipids / MALDI TOF MS / N-doped carbon dots / SR-FTIR spectroscopyIzvor:
Cancers, 2022, 14, 5, 1182-Finansiranje / projekti:
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200017 (Univerzitet u Beogradu, Institut za nuklearne nauke Vinča, Beograd-Vinča) (RS-MESTD-inst-2020-200017)
- ALBA Synchrotron, MIRAS [No. 2019093770] Beamline
- FCT(CQM Base Fund [UIDB/00674/2020]
- Programmatic Fund [UIDP/00674/2020]
- Madeira 14-20 Program (PROEQUIPRAM) [M1420-01-0145-FEDER-000008]
- ARDITI-CQM/2018/007-PDG [M1420-01-0145-FEDER-000005- CQM+ (Madeira 14–20)]
DOI: 10.3390/cancers14051182
ISSN: 2072-6694
WoS: 000771434100001
Scopus: 2-s2.0-85125205643
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Nešić, Maja D. AU - Dučić, Tanja AU - Algarra, Manuel AU - Popović, Iva A. AU - Stepić, Milutin AU - Gonçalves, Mara AU - Petković, Marijana PY - 2022 UR - https://vinar.vin.bg.ac.rs/handle/123456789/10184 AB - In the last decade, targeting membrane lipids in cancer cells has been a promising approach that deserves attention in the field of anticancer drug development. To get a comprehensive understanding of the effect of the drug [Ru(η5-Cp)(PPh3)2CN] (RuCN) on cell lipidic components, we combine complementary analytical approaches, matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI TOF MS) and synchrotron radiation-based Fourier transform infrared (SR-FTIR) spectroscopy. Techniques are used for screening the effect of potential metallodrug, RuCN, without and with drug carriers (carbon dots (CDs) and nitrogen-doped carbon dots (N-CDs)) on the lipids of the human ovarian cancer cell line A2780. MALDI TOF MS results revealed that the lysis of ovarian cancer membrane lipids is promoted by RuCN and not by drug carriers (CDs and N-CDs). Furthermore, SR-FTIR results strongly suggested that the phospholipids of cancer cells undergo oxidative stress after the treatment with RuCN that was accompanied by the disordering of the fatty acid chains. On the other hand, using (N-)CDs as RuCN nanocarriers prevented the oxidative stress caused by RuCN but did not prevent the disordering of the fatty acid chain packing. Finally, we demonstrated that RuCN and RuCN/(N-)CDs alter the hydration of the membrane surface in the membrane–water interface region. T2 - Cancers T1 - Lipid Status of A2780 Ovarian Cancer Cells after Treatment with Ruthenium Complex Modified with Carbon Dot Nanocarriers: A Multimodal SR-FTIR Spectroscopy and MALDI TOF Mass Spectrometry Study VL - 14 IS - 5 SP - 1182 DO - 10.3390/cancers14051182 ER -
@article{ author = "Nešić, Maja D. and Dučić, Tanja and Algarra, Manuel and Popović, Iva A. and Stepić, Milutin and Gonçalves, Mara and Petković, Marijana", year = "2022", abstract = "In the last decade, targeting membrane lipids in cancer cells has been a promising approach that deserves attention in the field of anticancer drug development. To get a comprehensive understanding of the effect of the drug [Ru(η5-Cp)(PPh3)2CN] (RuCN) on cell lipidic components, we combine complementary analytical approaches, matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI TOF MS) and synchrotron radiation-based Fourier transform infrared (SR-FTIR) spectroscopy. Techniques are used for screening the effect of potential metallodrug, RuCN, without and with drug carriers (carbon dots (CDs) and nitrogen-doped carbon dots (N-CDs)) on the lipids of the human ovarian cancer cell line A2780. MALDI TOF MS results revealed that the lysis of ovarian cancer membrane lipids is promoted by RuCN and not by drug carriers (CDs and N-CDs). Furthermore, SR-FTIR results strongly suggested that the phospholipids of cancer cells undergo oxidative stress after the treatment with RuCN that was accompanied by the disordering of the fatty acid chains. On the other hand, using (N-)CDs as RuCN nanocarriers prevented the oxidative stress caused by RuCN but did not prevent the disordering of the fatty acid chain packing. Finally, we demonstrated that RuCN and RuCN/(N-)CDs alter the hydration of the membrane surface in the membrane–water interface region.", journal = "Cancers", title = "Lipid Status of A2780 Ovarian Cancer Cells after Treatment with Ruthenium Complex Modified with Carbon Dot Nanocarriers: A Multimodal SR-FTIR Spectroscopy and MALDI TOF Mass Spectrometry Study", volume = "14", number = "5", pages = "1182", doi = "10.3390/cancers14051182" }
Nešić, M. D., Dučić, T., Algarra, M., Popović, I. A., Stepić, M., Gonçalves, M.,& Petković, M.. (2022). Lipid Status of A2780 Ovarian Cancer Cells after Treatment with Ruthenium Complex Modified with Carbon Dot Nanocarriers: A Multimodal SR-FTIR Spectroscopy and MALDI TOF Mass Spectrometry Study. in Cancers, 14(5), 1182. https://doi.org/10.3390/cancers14051182
Nešić MD, Dučić T, Algarra M, Popović IA, Stepić M, Gonçalves M, Petković M. Lipid Status of A2780 Ovarian Cancer Cells after Treatment with Ruthenium Complex Modified with Carbon Dot Nanocarriers: A Multimodal SR-FTIR Spectroscopy and MALDI TOF Mass Spectrometry Study. in Cancers. 2022;14(5):1182. doi:10.3390/cancers14051182 .
Nešić, Maja D., Dučić, Tanja, Algarra, Manuel, Popović, Iva A., Stepić, Milutin, Gonçalves, Mara, Petković, Marijana, "Lipid Status of A2780 Ovarian Cancer Cells after Treatment with Ruthenium Complex Modified with Carbon Dot Nanocarriers: A Multimodal SR-FTIR Spectroscopy and MALDI TOF Mass Spectrometry Study" in Cancers, 14, no. 5 (2022):1182, https://doi.org/10.3390/cancers14051182 . .